Drug Profile
Tislelizumab - BeiGene
Alternative Names: BGB-A317; TEVIMBRA; Tilelizumab; Tirelizumab - BeiGene; Tizveni; VDT-482Latest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator BeiGene
- Developer Asieris Pharmaceuticals; BeiGene; Celgene Corporation; HUTCHMED; Leap Therapeutics; Novartis; Tianjin Medical University
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hodgkin's disease; Liver cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Registered Gastric cancer; Nasopharyngeal cancer
- Preregistration Oesophageal cancer; Small cell lung cancer
- Phase III Cancer
- Phase II Bladder cancer; Cervical cancer; Colorectal cancer; Lung cancer; Lymphoma; Rectal cancer
- Phase I/II Endometrial cancer; Haematological malignancies; Triple negative breast cancer
- No development reported Ovarian cancer; Renal cancer
Most Recent Events
- 28 Feb 2024 BeiGene terminates a Phase-III SAFFRON-301 clinical trials in Non-small cell lung cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia and China (PO) due to safety risks and unfavorable risk-benefit assessment results (NCT04921358)
- 27 Feb 2024 Preregistration for Gastric cancer (Combination therapy, First-line therapy, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, In adults) in USA (IV)
- 27 Feb 2024 FDA assigns PDUFA action date of December 2024 for Tislelizumab for Gastric cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Metastatic disease, In adults, In the elderly)